Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exosome component 10 (EXOSC10) is a catalytically active 3'-5' exoribonuclease and a core subunit of the multi-protein RNA exosome complex, primarily located in the nucleus. EXOSC10 plays a crucial role in the 3'-5' processing and degradation of many RNA species, including rRNA, small nucleolar RNA (snoRNA), and defective mRNA[1][5]. It is involved in various cellular processes, such as ensuring the quality of RNA, regulating the maturation and elimination of RNA intermediates, controlling mRNA turnover, and participating in DNA repair via homologous recombination[1]. EXOSC10 is also implicated in cell proliferation, embryonic development, oogenesis, and spermatogenesis[1]. Autoantibodies directed against EXOSC10 (also known as PM/Scl-100) serve as important biomarkers in specific autoimmune disorders, including scleroderma and polymyositis[1]. No drugs currently target EXOSC10 directly. Although part of a major RNA degradation machinery associated with several cellular functions, EXOSC10 itself is not considered a canonical therapeutic target, and loss of function is likely incompatible with cell survival[1][5].
Not applicable, as no drugs target EXOSC10 directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exosome component 10 (EXOSC10).